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ABSTRACT
In this article, we show that high resolution melting
analysis (HRM) is a sensitive and specific method for
the detection of methylation. Methylated DNA and
unmethylated DNA acquire different sequences after
bisulphite treatment resulting in PCR products with
markedly different melting profiles. We used PCR
to amplify both methylated and unmethylated
sequences and assessed HRM for the determination
of the methylation status of the MGMT promoter
region. Reconstruction experiments showed that
MGMT methylation could be detected at levels as
low as 0.1%. Moreover, MS-HRM allows for estima-
tion of the methylation level by comparing the
melting profiles of unknown PCR products to the
melting profiles of PCR products derived from
standards with a known unmethylated to methylated
template ratio. We used MS-HRM for the analysis of
eight cell lines of known methylation status and a
panel of colorectal cancer specimens. The simplicity
and high reproducibility of the MS-HRM protocol
makes MS-HRM the method of choice for
methylation assessment in many diagnostic and
research applications.
INTRODUCTION
Methylation of cytosines allows the encoding of epigenetic
information directly onto the DNA. In the human
genome, methylated cytosines are found in CpG
dinucleotides whose palindromic nature allows for the
maintenance of methylation patterns by DNA methyl-
transferases following semi-conservative replication of
DNA. Regions of DNA with a relatively high CpG
dinucleotide content are referred to as CpG islands (1).
CpG islands are distributed in a non-random manner
across the human genome and often span the promoter
region and the ﬁrst exon of protein coding genes.
Methylation of individual promoter region CpG islands
usually acts to turn oﬀ (silence) transcription by recruiting
histone deacetylases thereby inducing the formation of
inactive chromatin (2).
Promoter region methylation of genes, particularly
those genes with pivotal functions in relation to tumour
suppression, apoptosis and DNA repair is one of the
hallmarks of cancer (2). Alterations of the pattern of
DNA methylation are an early event in cancer and
continue on through the evolution of the cancer.
Furthermore, distinct tumour types often have character-
istic signatures of methylated genes (3,4) and these can be
used as markers for early detection and/or monitoring the
progression of carcinogenesis. More importantly, the
methylation of certain genes, in particular DNA repair
genes, can cause sensitivity to speciﬁc chemotherapeutics
and methylation of those genes can thereby act as a
predictive marker if those chemotherapeutic agents are
used (5).
The methylation status of the MGMT gene has been
shown to be a predictive marker in various cancers treated
with alkylating agents (6–8). The MGMT protein removes
methyl/alkyl adducts from the O
6-position of guanine and
therefore protects the cell from undergoing transition
mutations. The tumour-speciﬁc methylation of the
MGMT promoter and subsequent abolition of MGMT
protein activity will render tumour cells susceptible to
alkylating agents used in cancer chemotherapy.
Consistent with this, the survival of patients whose
tumour was methylated at the MGMT promoter was
signiﬁcantly longer than that of patients with tumours
that did not show methylation of MGMT when those
patients were treated with alkylating agents (6–8).
*To whom correspondence should be addressed. Tel: þ61 3 9656 1807; Fax: þ61 3 9656 1460; Email: alexander.dobrovic@petermac.org
Correspondence may also be addressed to Tomasz K.Wojdacz. Email: wojdacz@humgen.au.dk
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Currently, no methylation detection method has been
established for reliable, fast and cost-eﬀective locus
speciﬁc methylation testing that is readily applicable for
both research and diagnostic settings. The research-based
methods have various limitations and pitfalls and contra-
dictory results can be obtained using diﬀerent protocols,
therefore none of them have found ready applicability in
diagnostics (9).
A new more reliable method for promoter methylation
analyses in clinical samples is needed. The new approach
reported here is based on high resolution melting (HRM)
which was originally developed for SNP genotyping (10).
HRM relies upon on the precise monitoring of the change
of ﬂuorescence as a DNA duplex melts. Like many real-
time PCR techniques, HRM utilizes the ability of certain
dyes to ﬂuoresce when intercalated with double-stranded
DNA. Two advances have made high resolution melting
possible. The ﬁrst is the introduction of intercalating dyes
that do not inhibit PCR reactions at the concentrations
necessary for them to fully saturate the target DNA
duplexes (10). The second is the development of instru-
mentation that is able to monitor the changes of
ﬂuorescence with high accuracy.
We have applied HRM technology to the detection of
methylation. By comparing the melting proﬁles of
unknown samples with the proﬁles of fully methylated
and unmethylated references ampliﬁed after bisulphite
modiﬁcation, we were able to detect methylation with high
sensitivity and moreover estimate the extent of methyla-
tion of the screened samples.
MATERIALS AND METHODS
DNA samples and controls
Colorectal cancer samples were provided by the Peter
MacCallum Cancer Centre Tissue Bank. DNA was
extracted from those samples by using the DNeasy
Tissue Extraction Kit (Qiagen, Hilden, Germany) follow-
ing the manufacturer’s protocol. DNA from cell lines was
puriﬁed by using the salting out method (11). As a
positive/methylated control in our experiments, we used
CpGenome
TM Universal Methylated DNA (Chemicon,
Millipore, Billerica, MA). DNA from peripheral blood
mononuclear cells was used as a negative/unmethylated
reference. To create the range of methylated and
unmethylated allele dilutions, the above two controls
were mixed in 0.1, 1, 10 and 50% methylated to
unmethylated template ratios. Each of our experimental
runs included the range of methylated/unmethylated
standards.
Bisulphitemodification
We used the MethylEasy
TM Kit (Human Genetic
Signatures, Sydney, Australia) for bisulphite modiﬁcation
of the DNA. The starting amount of DNA for all the
bisulphite modiﬁcations was 1mg and all the modiﬁcation
reactions were performed according to the manufacturer’s
protocol with the exclusion of the second 70%
ethanol wash.
High resolution melting analysis (HRM)
PCR ampliﬁcation and high resolution melting analysis
were carried out sequentially on a Rotor-Gene
TM 6000
(Corbett Research, Mortlake, Australia). PCR was carried
out in a 20ml total volume containing: 1  Buﬀer, 4mM
Mg
þ2, 200mM of each of the four dNTPs, 250 nM of each
primer, 5mM Syto9 dye (Invitrogen, Carlsbad, CA), 1U
HotStarTaq polymerase (Qiagen) and 1ml of bisulphite
modiﬁed template (theoretical concentration 20ng/ml).
The ampliﬁcation consisted of 15min at 958C, followed
by 50 cycles of 5s 958C, 5s at the primer annealing
temperature (Ta) and 10s at 728C. High resolution melting
analyses were performed at the temperature ramping and
ﬂorescence acquisition setting recommended by the
manufacturer i.e. temperature ramping from 70–958C,
rising by 0.18C/2s. All the reactions were performed in
triplicate. The melting curves were normalized by calcula-
tion of the ‘line of best ﬁt’ in between two normalization
regions before and after the major ﬂuorescence decrease
representing the melting of the PCR product using the
software provided with the Rotor-Gene
TM 6000. This
algorithm allows the direct comparison of the samples that
have diﬀerent starting ﬂuorescence levels.
MGMT MethylLightassay
The MGMT MethylLight assay used for validation of our
experiments was as previously reported (12). The reaction
consisted of: 1  Buﬀer, 4mM Mg
þ2, 200mM of each of
the four dNTPs, 500nM of each primer, 200nM of probe,
1U HotStarTaq polymerase and 1ml of bisulphite-
modiﬁed template (theoretical concentration 20ng/ml).
The real-time ampliﬁcations were carried over and
analysed on a Rotor-Gene
TM 3000 machine (Corbett
Research). After 15min at 958C, 50 cycles of 958C for 15s
and 608C for 30s were performed. The assay was
optimized on the same range of methylated/unmethylated
template mixes as in MS-HRM analyses. All the PCR
ampliﬁcations were performed in triplicate.
MGMT MS-HRMand BNIP3MS-HRM assays
The primer sets for all MS-HRM assays were designed
according to the principles recently set out to compensate
for PCR bias (13). The primers were designed to amplify
both methylated and unmethylated template. The primers
used and the ampliﬁed sequences are shown in Table 1.
RESULTS
The sensitivity of theMS-HRM assay
The sensitivity of the MGMT MS-HRM assay was tested
by using dilutions of fully methylated control DNA into
peripheral blood DNA. The inclusion of CpGs in the
primer sequence gave us the possibility to direct the PCR
bias towards the methylated templates by manipulating
the annealing temperature of PCR ampliﬁcation and
therefore making our assays more sensitive for methyla-
tion detection. All assays showed annealing temperature-
dependent sensitivity (Figure 1). The ﬁrst assay that we
designed (MGMT MS-HRM1) targeted a 175-bp long
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did not give reproducible methylation signals at the 0.1%
methylation measurement point. We addressed this by
redesigning the primers to amplify shorter fragments of
the template. Two new assays MGMT MS-HRM2 and
MGMT MS-HRM3 ampliﬁed fragments of 109 and 94bp,
respectively (Table 1). Both MGMT MS-HRM2 and
MGMT MS-HRM3, when run at the annealing tempera-
ture that signiﬁcantly favoured ampliﬁcation of methy-
lated template, were able to reproducibly detect
methylation in the samples containing 0.1% methylated
template shown in Figure 2B and C.
ProfilingofmethylationcontentofthesamplesbyMS-HRM
We tested the consistency of normalized melting proﬁles
derived from samples with diﬀerent ratios of methylated
and unmethylated template. The normalized melting
proﬁles of the PCR product ampliﬁed from the same
mix of methylated and unmethylated template were
consistent between replicates and between diﬀerent runs
(data not shown). Furthermore, the shapes of normalized
melting proﬁles were ampliﬁcation independent as samples
with diﬀerent starting amount of template displayed very
similar proﬁles.
The consistency of HRM proﬁles allows the design of
MS-HRM for estimation of the methylation content of
unknown samples on the basis of similarities of normal-
ized HRM proﬁles. Nevertheless, when designing
MS-HRM, the length and the number of diﬀerences
between methylated and unmethylated PCR products
needs to be taken into account. A short product will give
high sensitivity but limited resolution between diﬀerent
levels of methylation because of the smaller diﬀerences in
melting proﬁles between methylated and unmethylated
products (Figure 2 and unpublished data). On the other
hand, a longer product will give readily distinguishable
HRM proﬁles for PCR products derived from samples
with diﬀerent ratios of methylated and unmethylated
template which will allow for the estimation of the
methylated proportion of an unknown sample on the
basis of similarities of HRM proﬁles of standards and
unknown (Figures 1, 3A and 4). However, the annealing
temperature at which the PCR ampliﬁcation is in
equilibrium between methylated and unmethylated pro-
duct has to be empirically determined prior to analyses.
Validation ofMS-HRM results against theMethylLight
assay
We validated the performance of the MGMT MS-HRM1
assay against a previously described MethylLight assay
for the MGMT promoter region (12). In our hands, the
performance of the MGMT MS-HRM1 assay for the
detection of MGMT promoter region methylation was
equivalent to the MethylLight assay as both of the assays
gave reproducible results until the 0.1% methylation
dilution (data not shown). However, the sensitivity
of the MGMT MS-HRM2 and MS-HRM3 assays were
superior to that observed for the MethylLight MGMT
assay (12). MGMT MS-HRM2 as well as MGMT
MS-HRM3 gave fully reproducible methylation signals
from the standard sample containing 0.1% methylated
template in the background of unmethylated DNA (data
not shown).
Application ofthe MGMT MS-HRM assayto cell lines
We also tested DNA from eight cell lines (MDA-MB-468,
HS578T, SW480, MDA-MB-435, MDA-MB-231, PC3,
T47D and SW48) for which the methylation status of the
MGMT promoter had been previously reported (14) by
using the MGMT MS-HRM1, MGMT MS-HRM3 and
MethylLight assays. Four of the eight cell lines studied
(SW480, MDA-MB-435, MDA-MB-231 and SW48)
showed complete (100%) methylation (Figure 3).
HS578T displayed a less characteristic melting proﬁle
which we interpreted as being due to heterogeneous
methylation. Whereas there was no evidence for hetero-
duplex formation between PCR products arising from
unmethylated and fully methylated templates, heterodu-
plexes could form if the individual PCR products diﬀered
at only a few bases. Therefore, the curve was diﬀerently
shaped as a consequence of complex melting pattern of
multiple heteroduplexes (Figure 3). The results from
MGMT MS-HRM were consistent with MethylLight
data for the cell lines (Figure 3B).
Application ofthe MGMT-MS-HRM assayto clinical
specimens
The diagnostic applicability of MS-HRM assay was tested
on a panel of 19 colorectal cancer samples. The MGMT
MS-HRM3 assay was used in those experiments and we
Table 1. Primers, regions ampliﬁed and amplicon’s information for the MS-HRM assays
Assay name Primer sequences Position (UCSC Genome
Browser, March 2006)
Screened CpGs/amplicon length
MGMT MS-HRM1 F- GCGTTTCGGATATGTTGGGATAGT chr10:131,155,459-131,155,631 18/173bp
R- CCTACAAAACCACTCGAAACTACCA
MGMT MS-HRM2 F- GCGTTTCGGATATGTTGGGATAGT chr10:131,155,459-131,155,568 12/109bp
R- AACGACCCAAACACTCACCAAA
MGMT MS-HRM3 F- CGTTTGCGATTTGGTGAGTGTT chr10:131,155,538-131,155,631 5/94bp
R- CCTACAAAACCACTCGAAACTACCA
BNIP3 MS-HRM F- GGTTGCGGGATGTGTTTTAGTTG chr10:133,645,340-133,645,467 13/128bp
R- ACCCCGCCCTACCCTATAAATTC
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MethylLight assay (12). MS-HRM assays detected
MGMT methylation in 8 of the 19 samples (42%).
However, two of the above samples showed a very low
methylation level (less than the 0.1% standard).
Methylation of one of the above samples was only detect-
able by the MGMT-MS-HRM3 assay. We repeated all the
runs to test the reproducibility of our results in between two
diﬀerent experiments and obtained identical results.
Verification ofaccuracy of MS-HRMapproach: BNIP3
MS-HRM assay
To verify that the MS-HRM approach is widely applicable
in methylation studies, we developed a MS-HRM assay
for the promoter region of BNIP3 (Table 1). BNIP3 has
been reported to undergo aberrant methylation in various
cancer types (15–17). As with the MGMT MS-HRM
assay, we used the range of methylated/unmethylated
mixes at diﬀerent PCR annealing temperatures to
determine the best conditions. In this model system, the
BNIP3 MS-HRM assay was able to unambiguously detect
methylation at the 0.1% level (Figure 4). During evalua-
tion of this assay, we performed the BNIP3 MS-HRM
Figure 1. The eﬀect of annealing temperature on the sensitivity of the
MS-HRM assay. The MGMT MS-HRM1 assay was run at the
following annealing temperatures. (A)6 0 8C, (B)6 2 8C and (C)6 3 8C.
Figure 2. The sensitivity of diﬀerent MS-HRM assays for MGMT
methylation. (A) MGMT MS-HRM1, (B) MGMT MS-HRM2 and
(C) MGMT MS-HRM3. All the assays were run at the annealing
temperature of 648C which enables the highest sensitivity of methyla-
tion detection. The results from the 0.1% methylation dilution for
MGMT MS-HRM1 were not reproducible between replicates and this
dilution was excluded from the ﬁgure.
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methylation study. Three of the cell lines SW480,
MDA-MB-435 and SW48 were methylated at the BNIP3
promoter (data not shown). The assay was also used to
test for methylation of the panel of 19 colorectal
cancer samples. Methylation of the BNIP3 promoter
sequence was detected in 12 out of 19 (63%) of colorectal
cancer samples. The methylation levels of 8 of these
samples (42%) were less than 10% with 3 of them
displaying 0.1% or less methylation (Figure 4). All the
results were reproducible between replicates (data not
shown).
DISCUSSION
There are many methods for the analysis of methylation
at individual loci, each with their characteristic strengths
and weaknesses (9). However, only a few protocols have
gained widespread use. Genomic sequencing can be
considered the gold standard (18,19). It provides the
most detailed information but its sensitivity is relatively
low (about 20%) and it is generally unsuitable for
screening because it is expensive to run, particularly
when individual clones are analysed. Pyrosequencing,
which has been recently introduced, is more sensitive
(about 5%) but is dependent on the availability of the
proprietary instrumentation (20).
Figure 3. Validation of the MGMT MS-HRM1 assay by the MGMT
MethylLight assay. The samples are the series of dilution standards and
three of the cell lines (MDA MB 468, SW480 and HS578T). Panel A
shows the MGMT MS-HRM1 assay and panel B shows the
MethylLight assay. The MS-HRM assay was run at an annealing
temperature of 618C.
Figure 4. The MS-HRM assay for BNIP3 methylation. Results of the
BNIP3-MS-HRM assay for ﬁve clinical samples compared to the
dilution standards. Samples 1–5 show diﬀerent methylation levels. The
samples have been distributed over three panels to help distinguish the
individual samples.
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PCR (MSP) that uses primers speciﬁc for methylated,
bisulphite-modiﬁed DNA (21). Unmethylated sequences
are not normally ampliﬁed unless primers speciﬁc for
unmethylated bisulphite modiﬁed DNA are designed.
Despite its widespread use, MSP has a number of
important limitations (9,22). As with other techniques
that rely on PCR primer 30 mismatching to give speciﬁcity,
false positives can arise if primers are badly designed or
used at too low a temperature. MSP is very sensitive but is
not quantitative. This can lead to the classiﬁcation of a
tumour as being methylated for a gene when a small
minority of cells only is positive, or more seriously, if the
bisulphite conversion of the DNA is incomplete.
Consistent with these reservations, in the recent trial of
temozolomide in glioblastoma, it was reported that testing
for MGMT methylation using MSP gave ‘highly variable
and centre-dependent’ results (8).
The majority of applications in methylation studies
utilize methylation-independent PCR (MIP) where the
primers are designed to amplify the bisulphite-modiﬁed
sequence regardless of its methylation status. However,
the standard algorithms for the design of MIP primers and
the protocols used do not always lead to the proportional
ampliﬁcation of methylated and unmethylated sequences
(13,20,23). As it is often diﬃcult to avoid CpG dinucleo-
tides in primers designed to amplify CpG islands, some
authors have suggested that the Cs in CpG sequences in
primers get replaced by a mismatched base (19). Other
authors have suggested that since the purpose of these
assays is to detect methylation, some bias towards
methylated sequences is acceptable and that a limited
number of CpGs can be included in the primers,
particularly if they are placed away from the 30 end (24).
More recently, it has been shown that some CpGs are
necessary in the primer sequence, otherwise PCR bias can
lead to a signiﬁcant underestimate of the degree of
methylation (13). We have accordingly adopted the
strategy of using primers containing limited numbers of
CpGs and manipulating the annealing temperature to
control the bias of PCR ampliﬁcation in the design of
MS-HRM assays. At lower annealing temperatures,
the primers bind both methylated and unmethylated
templates and PCR bias will favour the ampliﬁcation of
unmethylated sequences. At higher annealing tempera-
tures, primer binding will favour methylated sequences,
and thus at the optimal annealing temperature, ampliﬁca-
tion is eﬀectively independent of methylation status.
Therefore, MS-HRM can be used to estimate the propor-
tion of methylation of a sample when run with standards.
This is especially important when assessing clinical cancer
samples for predictive markers such as MGMT where
discrimination between tumour specimens that are methy-
lated in all cells of the tumour from those that only show
methylation in a small subset of their cells may have
prognostic value. In the ideal situation, an estimate of the
proportion of tumour cells in the sample will be given by
pathological examination of the tissue and this can be
compared with the estimated proportion of DNA that is
methylated. Furthermore, if the tumour samples are of
high purity, they can be used to determine whether the
tumour is homozygously or heterozygously methylated.
The technique would also be applicable to the diagnosis of
imprinting disorders that are characterized by the abnor-
mal methylation of imprinted genes.
High resolution melting relies on the use of high
sensitivity ﬂorescence detection instrumentation, fully
saturating intercalating dyes and software allowing the
analysis of the melting proﬁles of PCR products. We
developed HRM for discrimination between methylated
and unmethylated sequences after bisulphite modiﬁcation
of the target DNA. Sodium bisulphite converts unmethy-
lated cytosines to uracil and leaves methylated cytosines
intact. Therefore, the PCR product derived from a
methylated template will have a higher melting tempera-
ture than that from an unmethylated template and those
diﬀerences can be resolved by melting analysis.
We have shown that HRM is applicable for the very
sensitive detection of methylation in an unmethylated
background. With MS-HRM, we were able to unambigu-
ously detect the methylated fraction of DNA in samples
containing as little as 0.1–1.0% of methylated DNA, the
same range as seen for the MethylLight assay (25).
MS-HRM is an in-tube method meaning that the
analysis takes place without the PCR product leaving
the tube that it was ampliﬁed in. This is of importance for
diagnostic laboratories not only because of the rapidity
that it aﬀords, but also the elimination of PCR product
contamination which has proven to be a major problem
both in research and the diagnostic settings.
An in-tube strategy based on the analysis of derivative
peaks of melting curves of PCR products to assess
methylation has already been reported (26,27). This has
not become widely used presumably because of the
diﬃculty of the suggested guidelines for assay design and
the technical limitations of reagents, instrumentation and
data analysis software which have now been overcome
since the development of HRM methodology.
MethylLight, the other in-tube method, is used by a
greater number of laboratories. It is a quantitative
adaptation of MSP that uses TaqMan probes. Whereas
MethylLight assays methylation of CpG sites covered by
the primers and probe, MS-HRM scans all of the CpGs
ﬂanked by the primers-binding to the target sequence,
regardless of the methylation status of CpGs in the primer-
binding side. Thus, the results of MS-HRM are not
compromised by heterogeneous methylation of a particu-
lar CpG dinucleotide or incomplete conversion of some of
CpGs within the template, as the latter will fall below the
limits of resolution. Heterogeneous methylation can read-
ily be distinguished from homogeneous methylation by the
shape of the curves as seen for HS678T. Moreover, the use
of probes in MethylLight complicates the design and
increases the costs of experiments. Also quantitative
MethylLight requires normalization against a reference
assay which needs to be run for each sample (24). By
contrast, MS-HRM does not require a reference assay for
normalization. All of the above make MethylLight
experiments relatively complex and expensive.
In summary, MS-HRM is a new approach that can be
readily applied to the methylation analysis of MGMT.
It can also be readily extended to other loci as we have
e41 Nucleic Acids Research, 2007, Vol. 35, No. 6 Page6 of7shown for the the BNIP3 locus. The sensitivity of MS-
HRM allows for detection of even a very small fraction of
methylated material which is of importance as tumour
samples may contain a low proportion of methylated
sequences due to the presence of signiﬁcant amounts of
normal tissue or heterogeneity of the tumour.
Furthermore, the high reproducibility and cost eﬀective-
ness of HRM makes this method suitable for both
research and diagnostic applications.
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